# MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

> **NCT01770353** · PHASE1 · COMPLETED · sponsor: **Ipsen** · enrollment: 45 (actual)

## Conditions studied

- Solid Tumors
- ER/PR Positive Breast Cancer
- Triple Negative Breast Cancer
- Metastatic Breast Cancer With Active Brain Metastasis

## Interventions

- **DRUG:** Ferumoxytol
- **DRUG:** MM-398

## Key facts

- **NCT ID:** NCT01770353
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2018-10-02
- **Final completion:** 2018-10-02
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01770353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01770353, "MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01770353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*